Vancouver-based SaNOtize Raises $24 Million in Series-B Financing to Advance Its Nitric Oxide-Based Therapeutics. Vancouver, BC, August 26, 2022 Vancouver-based SaNOtize Research & Development Corp., an anti-infective-focused therapeutics company, announced an oversubscribed $24 million Series-B funding round to advance its nitric oxide-based therapeutics pipeline.
Co-led by Horizons Ventures and OurCrowd, new funding enables SaNOtize to invest in its ongoing Phase 3 clinical trial for COVID-19 prevention and enhance clinical development of its other nitric
Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR
MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development
MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) - peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize's Nitric Oxide Nasal Spray (NONS) study titled: 'SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial'. https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext "We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in